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Stimulated  by recent  advances  in malaria  control  and increased  funding,  the  elimination  of  malaria  is
now  considered  to be an  attainable  goal  for an increasing  number  of  malaria-endemic  regions.  This  has
boosted  the  interest  in  transmission-reducing  interventions  including  vaccines  that target  sexual,  sporo-
genic,  and/or  mosquito-stage  antigens  to interrupt  malaria  transmission  (SSM-VIMT).  SSM-VIMT  aim  to
prevent  human  malaria  infection  in vaccinated  communities  by  inhibiting  parasite  development  within
the  mosquito  after  a blood  meal  taken  from  a gametocyte  carrier.  Only  a handful  of target  antigens  are
in clinical  development  and  progress  has  been slow  over the years.  Major  stumbling  blocks include  (i)
the  expression  of appropriately  folded  target  proteins  and  their  downstream  puriﬁcation,  (ii) insufﬁ-
cient  induction  of sustained  functional  blocking  antibody  titers  by  candidate  vaccines  in humans,  and
(iii)  validation  of a  number  of (bio)-assays  as correlate  for blocking  activity  in the  ﬁeld.  Here  we discuss
clinical  manufacturing  and testing  of  current  SSM-VIMT  candidates  and  the  latest  bio-assay  develop-
ment  for  clinical  evaluation.  New  testing  strategies  are  discussed  that  may  accelerate  the  evaluation  and
application  of  SSM-VIMT.
© 2015  Published  by Elsevier  Ltd.  This  is  an open  access  article  under  the  CC BY  license
(http://creativecommons.org/licenses/by/4.0/).
1. Introduction
The World Malaria Report 2014 documented major progress
with a considerable reduction of the malaria burden in several
countries. In sub-Saharan Africa, average infection prevalence in
children aged 2–10 years showed a decline of 48% since the year
2000 with similar decreases in malaria-attributed mortality [1]. In
addition to the prevention and treatment of clinical cases, reduction
of malaria transmission forms a fundamental basis of malaria con-
trol and elimination. As new tools are developed, their impact on
malaria parasite transmission can be quantiﬁed and malaria elimi-
nation may  become a realistic endeavor for an increasing number of
settings. Transmission reduction may  thereby become a key metric
in measuring the impact of new tools and combinations of interven-
tion methods. Vaccines interrupting malaria transmission (VIMT),
introduced in the malaria vaccine roadmap (reviewed in [2]), that
effectively interrupt transmission from humans to mosquitoes have
the potential to ﬁll a critical gap in the malaria vaccine portfolio.
Such vaccines aim to reduce the spread of the parasites among
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humans by preventing infection of Anopheles vectors and represent
highly relevant tools for the accomplishment of malaria elimination
and eradication. Traditionally only sexual- and sporogonic anti-
gens have been considered transmission blocking vaccine targets
but more recently pre-erythrocytic vaccines have been included
because these – if highly effective – prevent parasitaemia and thus
generation of gametocytes and onward transmission [2,3]. Pre-
erythrocytic vaccines have the advantage that they confer direct
personal protection while only delayed personal protection can
be expected from vaccines directed exclusively against sexual-
sporogonic-mosquito stages (SSM-VIMT).
Already in the 1950s, it was  shown that immunization of
chickens with a mix  of asexual-and sexual stages of Plasmodium
gallinaceum blocked parasite infectivity [4]. Twenty years later, it
appeared that antibodies against target antigens on sexual stages
were responsible for the observed transmission blocking effects
in this model and that these antibodies acted after ingestion by
mosquitoes [5,6]. Antibodies can destroy gametes and zygotes
up to several hours after a mosquito blood meal and can com-
pletely prevent infectivity to mosquitoes. The ﬁrst description of
mosquito feeding assays, that form a cornerstone of assessments
of transmission blocking immune responses, dates from the 1950s
[7]. In the decades that followed, experimental mosquito mem-
brane feeding systems were optimized and monoclonal antibody
technology became available. This resulted in the development
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of the standard membrane feeding assay (SMFA) and a series of
sexual stage proteins were deﬁned as targets for transmission
blocking antibodies ([8–10], reviewed in [11]). The genes encoding
Pfs48/45, Pfs230 and Pfs25 in Plasmodium falciparum as well as its
ortholog Pvs25 in Plasmodium vivax, were isolated and these target
proteins remained the major candidates for clinical development
of transmission blocking vaccines for already for the past three
decades [12–15]. During this period, several workshops have been
organized by, amongst others, the World Health Organization, the
United States National Institutes of Health (NIH), Malaria Vaccine
Initiative and the Bill & Melinda Gates Foundation to discuss clinical
trial design and endpoints, efﬁcacy evaluation assays, regulatory
aspects and application strategies [2,3,16–18]. Major challenges in
this endeavor have been (i) incomplete/inadequate conformation
of vaccine proteins and the production of clinical grade material;
(ii) absence of validated standards and assays for clinical efﬁcacy;
(iii) absence of a rapid pipeline of proof-of-principle human trials
for testing lead candidates. Here, we will discuss the latest progress
in clinical development of SSM-VIMTs and evaluation of biological
endpoint measures with suggestions for future steps.
2. SSM-VIMT candidates in clinical development
Transmission blocking immunity relies on functional antibodies
against surface membrane proteins on sexual/sporogonic stages or
mosquito midgut antigens. Pre-fertilization antigens are expressed
in gametocytes in the human host but only become accessible for
functional antibody binding once gametocytes emerge from the
red blood cells to form gametes in the mosquito midgut. Nat-
urally acquired- or experimentally-induced antibodies can bind
to gametes, thereby preventing fertilization and zygote forma-
tion. Pre-fertilization antigens expressed in humans can induce
antibodies after natural infection thereby creating the possibil-
ity to boost and/or enhance vaccine induced antibody titers and
longevity [19–21]. Post-fertilization transmission blocking target
antigen expression occurs in the mosquito midgut in zygotes and
ookinetes [10,22]. There is currently no evidence that these pro-
teins are expressed in gametocytes in the human circulation and
therefore the human immune system is not exposed to these pro-
teins and naturally acquired antibodies are not detectable [23,24].
Although a substantial number of targets have been identiﬁed and
tested in preclinical studies over the past decades, the lead vaccine
candidates have not changed and include pre-fertilization pro-
teins Pfs48/45 [8,10] and Pfs230 [25] and post-fertilization antigen
Pfs25 [10]. Recombinant P25 proteins have been successfully gen-
erated for both P. falciparum and P. vivax [26,27]. In a very different
approach, mosquito derived targets have been identiﬁed that are
involved in egress of the ookinete stages from the midgut repre-
sented by AnAPN1 [28], also forming a starting point for SSM-VIMT
development.
2.1. Pfs48/45
Pfs48/45 is expressed in gametocytes once the parasite under-
goes sexual differentiation in the human host and plays a critical
role in male gamete fertility [29]. Pfs48/45 is a member of a protein
family deﬁned by a disulﬁde bonding pattern of six conserved
cysteine residues and glycosylphosphatidylinositol (GPI) anchored
in the membrane [30]. The transmission blocking B-cell epitopes
fully depend on tertiary structures [31] with an N-terminal domain
with epitope V, a central domain that comprises epitopes II and III,
and a C-terminal domain containing the most potent transmission
blocking epitope I [32]. The most effective target for transmission
blocking antibodies is epitope I, while antibodies against epitopes
II and III are less potent but show complementary functionality
in suppression of infectivity to mosquitoes [33,34]. Although a
well-established SSM-VIMT since the gene was cloned in 1993,
Pfs48/45 has proven to be a difﬁcult target for production of appro-
priate conformers in multiple heterologous expression systems
[13,35–38]. Signiﬁcant progress was  made with production of the
10-C fragment, containing 10 cysteines (residue 159–428) in fusion
with Maltose Binding Protein in Escherichia coli [35]. While gener-
ating appropriate conformers and inducing transmission blocking
antibodies in mice, the yield remained low after puriﬁcation [35].
These challenges were partly overcome by a correctly-folded
functional fragment of Pfs48/45 (10C) as a chimeric antigen fused
in frame with a section of GLURP (GLURP.RO) in Lactococcus lactis.
Puriﬁed R0.10C induced functional antibodies in rats showing
strong transmission blocking activity [37]. A fully current good
manufacturing process (cGMP) compatible production and down-
stream puriﬁcation process of R0-10C has been established at
industrial scale in collaboration with Gennova Biopharmaceuticals
(India) (Sauerwein, unpublished). Formulation conditions are
currently optimized in preparation for clinical testing.
2.2. Pfs230
Production of Pfs230 starts in immature gametocyte stages as a
363-kD precursor protein of 70 cysteine residues, which is subse-
quently processed into 300- and 307-kDa fragments [14,39]. In the
apparent absence of a GPI anchor, these fragments are expressed in
stable complex with Pfs48/45 on the parasitophorous membrane
of gametocytes [30,39–41]. Once these parasite forms are acti-
vated and transformed into gametes, Pfs230 is readily accessible
on the membrane for binding to speciﬁc antibodies. Functionality
of anti-Pfs230 Mabs is dependent on complement ﬁxing isotypes
[25,42,43]. A study by Read et al. demonstrated that Mabs of a
complement-ﬁxing isotype prevented infectivity of P. falciparum
to mosquitoes in the presence of complement whilst none of the
tested Mabs of non-complement ﬁxing isotypes had transmission
reducing effects [44]. Due to its complexity, recombinant expres-
sion of full-length Pfs230 has never been achieved. Pfs230 fragment
C (residues 443–1132) contains epitopes for at least partial trans-
mission reduction and subsequently became the focus for clinical
vaccine development [45,46]. A puriﬁed portion of Pfs230 domain
C, 230CMB, (residue 444 to 730) expressed in a plant-based expres-
sion system induced fully blocking activity in the presence of
complement in rabbits qualifying as potential SSM-VIMT vaccine
candidate for clinical development [47].
2.3. Pfs25
Pfs25 has been in the lead position since 1983 when speciﬁc
and potent mAbs were shown to block transmission [10]. Pfs25
is a 25-kDa GPI-anchored surface protein containing four epider-
mal  growth factor (EGF)-like domains with 22 cysteines and 11
disulﬁde bonds [12]. The protein is shed from the membrane and
likely involved in ookinete adhesion and subsequent penetration
of the midgut [10,12]. The potent transmission blocking activity
of a panel of Mabs recognizing (linear and conformational) epi-
topes has greatly boosted subunit vaccine development [26,48].
Recombinant Pfs25 as well as P. vivax ortholog Pvs25 proteins
expressed in yeast, have been the only SSM-VIMTs tested in clin-
ical trials, ﬁrst as TBV25H that later became Pfs25H [49]. The ﬁrst
human phase 1 trial occurred in 1994 with P. falciparum TBV25H
absorbed to Alum where 1/8 volunteers experienced a hyper-
sensitivity reaction. Antibody titers were low with consequently
unsatisfactory results in the SMFA (Kaslow, unpublished) [49]. In a
second trial, TBV25H/alum was  used to boost a prime induced by
the virally vectored multi-antigen NYVAC-Pf7 that included Pfs25,
resulting in at least 75% oocysts reductions in the SMFA in 3/9
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volunteers [49]. Many modiﬁcations were employed to overcome
problems related to homogeneity and conformational integrity of
Pfs25H [50]. To increase potency a different adjuvant platform
was explored resulting in a clinical trial using Montanide ISA 51
rather than Alum [51]. However, this trial had to be terminated
due to occurring erythema nodosum reactions likely related to this
speciﬁc antigen/adjuvant combination and possibly also the case
for the observed transient leukemoid reactions. Sera from volun-
teers who completed two scheduled doses of Pfs25/ISA51 showed
functional activity in mosquito feeding assays. The ﬁrst clinical P.
vivax transmission blocking vaccine trial using recombinant Pvs25
formulated with Alhydrogel also induced too low levels of func-
tional blocking antibodies and oocyst reductions by >75% was not
obtained [52]. The major challenge for P25-based SSM-VIMT seems
the conditional induction of sustained high antibody titers. The
exact concentrations of anti Pfs25 abs in human serum required
for >75% oocyst reduction are not known but likely far more than
100 g/ml [10]; in contrast 15–50 g/ml of Pfs25 Mab  32F81 is suf-
ﬁcient for near complete blockade in laboratory and ﬁeld-based
mosquito feeding assays [53]. More recently some of these limita-
tions may  have been successfully addressed. Potent transmission
blocking activity was obtained in pre-clinical immunization stud-
ies using puriﬁed codon-harmonized Pfs25 expressed in E. coli [54],
with Pfs25 produced in chloroplasts of algae [55], with Pfs25 in
Chad63/modiﬁed vaccine virus [Kapulu et al. submitted,  2], with
Pfs25-IMX313 nanoparticles in Pichia pastoris [56] or with Pfs25
fused to a modiﬁed lichenase (LicKM) carrier in Nicotiana benthami-
ana plants [57]. Another promising approach for enhancing Pfs25
immunogenicity is conjugation to carrier proteins with known high
immunogenicity e.g. the outer membrane protein complex (OMPC)
of Pseudomonas aeruginosa [58]. The group at NIAID that pioneered
this approach with Merck scientists has subsequently moved a
Pfs25 protein conjugate vaccine into the clinic. Phase 1 human trials
of Pfs25 that is chemically conjugated to E. coli-expressed ExoPro-
tein A (EPA), the latter entity being a detoxiﬁed form of ExoToxin A
of P. aeruginosa is advancing to a Phase 1 trial by the NIAID group
in collaboration with the University of Bamako in Mali.
2.4. Mosquito antigen AnAPN1
Antivector SSM-VIMT can inhibit parasite development by
eliciting antibodies that prevent ookinete interaction with
mosquito midgut ligands. The Anopheline Alanyl aminopeptidase
N (AnAPN1) is originally isolated from the apical brush border
microvilli fraction of Anopheles gambiae midguts [28,59]. Next
to presence of a transmission-blocking epitope, the C-terminal
AnAPN1 fragment [60] also contains an immune-dominant decoy
epitope inducing non-blocking antibodies. This has delayed the
clinical development of AnAPN1. Based on the crystal structure
of the near-full length APN1[unpublished], a structure-guided
construct has been expressed in E. coli and is currently under inves-
tigation in transmission-blocking studies (Dinglasan R, personal
communication).
3. Biological endpoints of SSM-VIMT
Functional transmission blocking activity relies on antibodies
targeting surface membrane antigens on sexual/sporogonic stages
or mosquito midgut targets. Next to speciﬁcity, other aspects have
not been fully determined such as antibody concentration and qual-
ity e.g. the capacity to ﬁx complement or mediate opsonization
[43,61]. There is an obvious need for an immune correlate that will
mimic  ﬁeld conditions and reliably predict functionality of induced
antibodies against genetically diverse Plasmodium and Anopheles
variants.
3.1. The standard membrane feeding assay
The initial validation and prioritization of SSM-VIMT candidates
is guided by antibody tests and functional assays that prevent
infection of mosquitoes. The latter is envisaged to be part of
the critical pathway of testing efﬁcacy in SSM-VIMT vaccinated
communities. This is a major advantage of SSM-VIMT vaccines
over other malaria life-stages vaccines for which there is no evi-
dent biological endpoint. The standard membrane feeding assay
(SMFA) is the most widely used assay to determine the functional-
ity of transmission-blocking antibodies [62,63]; in vitro cultured
gametocytes are mixed with serum or puriﬁed antibodies and
fed through membrane feeders to laboratory-reared, uninfected
Anopheles mosquitoes. Two outcome measures of the SMFA are
the proportion of infected mosquitoes (oocyst prevalence) and
the infection burden (oocyst density) in mosquitoes. These out-
comes are commonly determined by microscopical examination
of mosquito midgut but can also be determined by the detec-
tion of parasite DNA by molecular methods [64,65] or parasite
protein by immuno-assays [65,66]. Recently, ﬂuorescence and
luminescence-based SMFA approaches have been proposed that
use P. falciparum strains expressing green ﬂuorescent protein [67]
and ﬁreﬂy luciferase protein [68]. Luciferase activity in the SMFA
closely relates to oocyst prevalence and density [68]. The SMFA
has traditionally been evaluated in terms of the reduction in oocyst
density compared to controls [69] which gives reproducible results
for potent antibody concentrations [70,71]. However, high densi-
ties of gametocytes as used in the SMFA and related oocyst densities
are not representative for natural infections [70–75]. It is, therefore,
difﬁcult to directly translate SMFA outcomes on a density scale
to a predicted impact on malaria transmission in the community
[74,76]. In order to reduce malaria transmission in a vaccinated
human population an SSM-VIMT will have to reduce oocyst preva-
lence – and not just mean oocyst densities – in mosquitoes feeding
on the vaccinated population. This is because even mosquitoes with
only one oocyst will produce salivary gland sporozoites [65] and
may be (equally) infectious, therefore, as mosquitoes with many
oocysts. Therefore, reducing oocyst densities may have little effect
on overall malaria transmission unless it also results in signiﬁ-
cant reduction in oocyst prevalence in the mosquitoes Although
oocyst prevalence and density are positively associated in experi-
ments, substantial reductions in density are needed to obtain lower
prevalence rates [70,71,77]. As a result, a relatively large number of
mosquitoes is needed for precise estimates of transmission reduc-
ing activity at the scale of mosquito infection prevalence [77]. The
SMFA can be adapted to make these estimates on the prevalence
scale more attainable. This can be achieved by diluting gameto-
cyte concentrations in feeders so that <50% of control mosquitoes
is infected [77] and by using scalable assessments of mosquito
infection status that obviate the need for mosquito dissection and
microscopy, such as the above described luciferase-based SMFA
[68].
An SMFA that is designed to obtain precise estimates of the
reduction in oocyst density appears fully justiﬁed, provided out-
come measures are presented on both the density and prevalence
scale [77,78]. For selected SSM-VIMT candidates, it is of great value
to test their efﬁcacy against a range of different oocyst densities in
control mosquitoes for a predicted biological efﬁcacy that is most
closely related to its public health endpoint i.e. reducing the prob-
ability that transmission from a human subject to a mosquito.
3.2. Immunological assays
Antibody concentrations against recombinant vaccine candi-
dates, as measured by conventional enzyme-linked immunosor-
bent assays (ELISA) have been shown to associate with SMFA
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outcome for anti-Pfs25 [24,79,80], Pvs25 [80], Pfs230 [24], Pfs48/45
antibodies [37]. For pre-fertilization antigens, the ability of sera to
recognize the native form of proteins can be further tested by quan-
titative ELISA where gametocyte extract is used for coating [37]
or by semi-quantitative immunoﬂuorescence assays that use ﬁxed
extracellular gametes (IFA) or live intact gametes in suspension
(SIFA) [35–37]. The quantiﬁcation of antibody recognition in these
assays has recently been improved by using luminescence rather
than ﬂuorescence as read-out (Roeffen, unpublished observations).
4. Public health impact of SSM-VIMT
Evidence from the ﬁeld and transmission models indicate that
the public health impact of SSM-VIMTs can be expected over all
levels of transmission intensity [75,81]. This will lead to a reduced
incidence of infections in all endemic areas and can accelerate the
path to elimination in low endemic settings (e.g. EIR <8 infectious
bites/year) [16] or an incidence of infection below 0.2/person/year
[82]). The minimum efﬁcacy of a SSM-VIMT to achieve these reduc-
tions in transmission intensity, and even the exact deﬁnition of
efﬁcacy, has recently been debated. Original workshops agreed
that high efﬁcacy in biological endpoints, ≥80% reduction in oocyst
intensity in the mosquito midgut [3,75], is needed to take can-
didates forward to clinical development and that higher efﬁcacy
will likely be only achieved by a multi-antigen vaccine. Recently
these assumptions were challenged by a population transmission-
model using rodent Plasmodium berghei and Anopheles stephensi
mosquitoes to determine the impact of transmission blocking inter-
ventions over multiple transmission cycles in different populations
with parasite prevalences that reﬂect different levels of trans-
mission intensity [76]. Using a transmission blocking drug, this
model has convincingly shows that the current go/no-go efﬁcacy
thresholds for an effective SSM-VIMT of ≥80% reduction in oocyst
density [3,75] may  be too stringent. Vaccine candidates may  be dis-
carded that induce lasting antibody levels and thereby contribute
to malaria elimination over several infection cycles [76]. This model
further shows that the efﬁcacy of SSM-VIMT strongly depends on
the local transmission intensity [75,76,81,82]. Important questions
for future SSM-VIMT application are the minimum vaccination cov-
erage and the duration of vaccine efﬁcacy. Unlike vaccines that aim
to protect high risk groups from (severe) disease, SSM-VIMT aim
for high coverage in the entirety of the human population that
contributes to malaria transmission. This reservoir comprises all
age groups [63,83]. SSM-VIMT application will in a way  resem-
ble mass drug administration campaigns for which high coverage
over repeated rounds has been shown to be a considerable chal-
lenge [84,85]. The required high and long-lasting antibody titers
will stress the need for optimized delivery platforms and adjuvants.
5. Biological endpoints of clinical trials in non-endemic
settings
5.1. Immunological and mosquito feeding assays in phase I trials
Sera from vaccinated individuals can be tested for immuno-
genicity but also for efﬁcacy in the SMFA and the direct membrane
feeding assays (DMFA). In the DMFA procedure, venous blood from
naturally infected gametocyte carriers is used as source of game-
tocytes and offered to locally reared mosquitoes in a membrane
feeder system similar to that used for the SMFA [86]. The DMFA
can support Phase I trials in non-endemic settings by allowing
assessment of functional activity of sera against gametocyte
infections from endemic settings [73]. This approach was  elegantly
illustrated in a Phase 1 clinical trial with Pfs25 that was  conducted
in the US and where transmission blocking activity was  induced
in a minority of vaccinees, as detected by SMFA [51]. One serum
sample was  further tested in the DMFA using gametocyte isolates
and mosquito colonies from Burkina Faso and Thailand [87]. These
DMFA experiments conﬁrmed the transmission blocking potential
of vaccination against a range of genetically complex, naturally cir-
culating parasite strains and illustrated the richness of information
obtained with these biological assays early in clinical testing.
6. Biological and public health endpoints of trials in
endemic settings
6.1. Immunological and mosquito feeding assays
The broader application of immune- and bioassays in Phase 1
and 2 studies in malaria endemic settings can directly quantify
the transmission potential of vaccinated gametocytaemic individ-
uals. In addition to SMFA and DMFA, Direct Feedings Assay (DFA)
are possible. In DFA laboratory-reared non-infected mosquitoes
are allowed to feed directly on the skin of gametocyte carriers;
the assay is more sensitive than DMFA, represents a more natu-
ral method but is subject to ethical considerations that limit the
number of mosquito observations, repeated assessments of infec-
tivity and the use in very young participants [86]. The most obvious
design of phase 2 studies in endemic settings would be an individual
randomized trial where vaccinated and non-vaccinated individuals
are compared for safety, immunogenicity and biological efﬁcacy of
vaccination. An alternative or complementary design could involve
a comparison of endpoints in trial participants before and after vac-
cination. This would be particularly valuable if individuals can be
identiﬁed who  are chronic carriers of infectious gametocytes and
whose infectiousness can be determined before and after vaccina-
tion. The biological endpoints of Phase 2 clinical trials in endemic
settings will allow determination of: (i) antibody concentration
and dynamics; (ii) dynamics of functional transmission blocking
activity in the SMFA with cultured gametocytes; (iii) dynamics of
functional transmission blocking activity in the DMFA with natu-
rally infected gametocyte donors; (iv) in a subset of vaccinees who
become gametocytaemic, functional transmission blocking activity
can be assessed by DMFA and DFA with naturally acquired game-
tocytes from the vaccinee. For a fully efﬁcacious vaccine, evidence
of (near) complete prevention of transmission and long-lived anti-
body responses make a strong case for accelerated approval where
the vaccine can be registered based on surrogate (biological) end-
points from mosquito feeding assays and where evidence for an
impact on public health endpoints is collected shortly after vaccine
implementation.
6.2. Cluster-randomized trials for public health endpoints
The ultimate objective of SSM-VIMT is to reduce the number
of incident infections in a population. There is currently no agree-
ment on whether surrogate endpoints of transmission measures
would be satisfactory for accelerated approval, especially if vac-
cine efﬁcacy is sub-optimal [82]. Two  relevant shortcomings of
mosquito infection outcomes are that they fail to quantify the
effect of the SSM-VIMT over repeated generations, thereby plau-
sibly underestimating efﬁcacy in reducing incident infections [76]
and the poorly parametrized association between reductions in
the likelihood that a mosquito becomes infected and the level of
malaria exposure experienced by a community. The conventional
approach would include Phase 1 and Phase 2 trials followed by
a large scale population based Phase 3 trial. This Phase 3 trial
will involve a cluster-randomized design and outcome measures
based on PCR-detected infection incidence with clinical endpoints
and safety evaluations as secondary objectives. The assumptions,
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outcome and design of a cluster randomized trial for SSM-VIMT
were recently reported as outcome of a series of expert meet-
ings [83]. The power and require sample size strongly depend on
the chosen settings and their characteristics in terms of transmis-
sion intensity (ideally intermediate intensity transmission; ∼0.6
incident infections/person/year), stability of transmission, other
malaria interventions, homogeneity of transmission between clus-
ters and migration of unvaccinated individuals into intervention
areas.
7. Conclusions and perspectives
Stimulated by recent advances in malaria control and increased
funding, the elimination of malaria is now considered to be an
attainable goal for an increasing number of malaria endemic
regions [88]. There is currently an unsurpassed momentum for
the development of SSM-VIMT to support elimination initiatives.
Despite very slow progress in the last decades, the ﬁrst clinical trial
with Pfs25-EPA is currently being undertaken in endemic settings
and, regardless of the efﬁcacy outcome of this trial, will lead to
considerable progress in our knowledge on how to conduct and
evaluate SSM-VIMT clinical trials. An alternative that has never
been fully explored is passive immunization with transmission
blocking monoclonal antibodies for preventing malaria transmis-
sion. The most potent monoclonal antibodies show full blocking
activity at micrograms per milliliter and achieving blocking concen-
trations in humans may  be feasible. Such an approach could serve
as a general proof of principle for SSM-TBV in endemic settings and
may  also be of value as an intervention in speciﬁc circumstances
such as malaria epidemics where SSM-TBV may  be of particular
value [23].
The assays to evaluate the biological efﬁcacy of SSM-VIMT have
been under scrutiny in recent years, leading to a better parametriza-
tion of different feeding assays, higher throughput systems, a range
of qualitative and quantitative tools for infection detection and
more robust analytical approaches [77]. Importantly, there has
been a timely investment in discussing the pathway of SSM-VIMT
development from pre-clinical to population studies. In addition
to assays with cultured gametocytes (SMFA) or naturally acquired
gametocytes (DMFA, DFA), it is conceivable to induce gametocy-
taemia in the Controlled Human Malaria Infection (CHMI) model
[89]. This model has been shown to be a powerful tool for evaluation
of antimalarial drugs [90], blood stage and pre-erythrocytic vaccine
candidates [91,92]. Early evidence for the induction of gametocytes
after CHMI was provided when mRNA of Pfs16, which is one of
the earliest expressed gametocyte-speciﬁc protein, was detected
48 h after the ﬁrst detection in the blood circulation of the 18s
rRNA of asexual parasites [93]. Blood-stage challenges in volun-
teers more recently provided evidence that mature gametocytes,
detected by microscopy and Pfs25 mRNA, can be induced following
drug treatment (McCarthy, 64th Annual Meeting of the Ameri-
can Society of Tropical Medicine & Hygiene, New Orleans 2014). If
these gametocytes are found in sufﬁciently high concentrations to
infect mosquitoes, this will pave the way to use CHMI-transmission
studies as part of the developmental pathway for SSM-VIMT devel-
opment. Cluster-randomized trials for SSM-VIMT are considered
as an ambitious but achievable approach. Because of the nature
of activity of SSM-VIMT and the changing malaria epidemiology
in many African and non-African settings [94], cluster-randomized
trials for SSM-VIMT will be amongst the most challenging inter-
vention trials in terms of implementation and monitoring. A careful
consideration of the optimum design of preceding clinical trials in
relation to a case for accelerated approval remains of great impor-
tance.
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